Concerning treatments for AiKDs due to NLRP1 mutations, the IL-1 receptor antagonist anakinra was reported to be effective in cases of NLRP1-associated autoinflammation with arthritis and dyskeratosis (43). This evidence concerns the gene NLRP1 and arthritic joint disease.